Total Payments
$144,099
2024 Payments
$98,806
Companies
4
Transactions
23
Medicare Patients
40
Medicare Billing
$910.18
Payment Breakdown by Category
Research$142,747 (99.1%)
Travel$1,227 (0.9%)
Food & Beverage$125.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $142,747 | 13 | 99.1% |
| Travel and Lodging | $1,227 | 8 | 0.9% |
| Food and Beverage | $125.00 | 2 | 0.1% |
Payments by Type
Research
$142,747
13 transactions
General
$1,352
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | $107,675 | 5 | $0 (2024) |
| Eli Lilly and Company | $36,299 | 16 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $100.00 | 1 | $0 (2019) |
| AbbVie Inc. | $25.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98,806 | 11 | Eli Lilly Export S.A. Puerto Rico Branch ($98,174) |
| 2023 | $1,780 | 4 | Eli Lilly and Company ($1,755) |
| 2022 | $19,261 | 2 | Eli Lilly and Company ($19,261) |
| 2021 | $6,102 | 2 | Eli Lilly and Company ($6,102) |
| 2020 | $18,051 | 3 | Eli Lilly Export S.A. Puerto Rico Branch ($9,501) |
| 2019 | $100.00 | 1 | Janssen Pharmaceuticals, Inc ($100.00) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $68,232.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | ||||||
| 09/27/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $8,960.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/27/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $1,281.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/23/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $19,701.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $545.60 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $50.93 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $31.22 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $1.52 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $0.93 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $0.90 | General |
| 04/15/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $0.49 | General |
| 05/24/2023 | Eli Lilly and Company | — | — | In-kind items and services | $600.01 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 04/13/2023 | Eli Lilly and Company | — | — | In-kind items and services | $560.01 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $595.40 | General |
| 03/01/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 10/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,807.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | ||||||
| 04/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $17,454.00 | Research |
| Study: A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 09/08/2021 | Eli Lilly and Company | — | — | In-kind items and services | $4,913.40 | Research |
| Study: A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 05/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $1,188.48 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 12/17/2020 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $9,501.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 12/17/2020 | Eli Lilly and Company | — | — | In-kind items and services | $1,251.18 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 10/29/2020 | Eli Lilly and Company | — | — | In-kind items and services | $7,298.32 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 05/30/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly Export S.A. Puerto Rico Branch | $68,232 | 1 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $22,367 | 2 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly Export S.A. Puerto Rico Branch | $19,701 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly Export S.A. Puerto Rico Branch | $9,501 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly Export S.A. Puerto Rico Branch | $8,960 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $7,298 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $2,440 | 2 |
| A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | Eli Lilly and Company | $1,807 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly Export S.A. Puerto Rico Branch | $1,281 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $600.01 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $560.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 40 | 40 | $910.40 | $910.18 |
Total Patients
40
Total Services
40
Medicare Billing
$910.18
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 20 | 20 | $570.20 | $569.98 | 100.0% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 20 | 20 | $340.20 | $340.20 | 100.0% |
About Dr. Luis Pagan, MD
Dr. Luis Pagan, MD is a General Practice healthcare provider based in Dorado, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831155092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Luis Pagan, MD has received a total of $144,099 in payments from pharmaceutical and medical device companies, with $98,806 received in 2024. These payments were reported across 23 transactions from 4 companies. The most common payment nature is "" ($142,747).
As a Medicare-enrolled provider, Pagan has provided services to 40 Medicare beneficiaries, totaling 40 services with total Medicare billing of $910.18. Data is available for 1 year (2021–2021), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Location Dorado, PR
- Active Since 04/25/2006
- Last Updated 10/28/2019
- Taxonomy Code 208D00000X
- Entity Type Individual
- NPI Number 1831155092
Products in Payments
- XARELTO (Drug) $100.00
- MAVYRET (Drug) $25.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Dorado
Elham Ghorbani, Md, MD
General Practice — Payments: $26,499
General Practice $26,499
Luis Pena Figueroa, M.d, M.D
General Practice — Payments: $2,482
General Practice $2,482
Carlos Robles
General Practice — Payments: $2,078
General Practice $2,078
Dr. Richard Connelly, M.d, M.D
General Practice — Payments: $1,203
General Practice $1,203
Mr. Blanca Plaza, Md, MD
General Practice — Payments: $863.32
General Practice $863.32
Melitsa Aguilar, M.d, M.D
General Practice — Payments: $737.23
General Practice $737.23